With wings clipped by FDA delay, bluebird's future is in doubt

7 March 2022
bluebird_bio_large

Midway through its annual report, Massachusetts-based gene therapy company bluebird bio (Nasdaq: BLUE) made the startling admission that it’s running out of cash, fast.

The admission may not come as too much of a surprise for investors, however, given the rocky road the company has faced making a business out of its rare disease innovations.

bluebird’s lead candidates are beti-cel for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy, both of which remain under review with the US Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology